Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

InSite One Inc.

This article was originally published in Start Up

Executive Summary

InSite One hopes to provide hospitals with an archiving solution that accommodates radiologists' needs for on-line and off-line storage of images and short and long-term access to those images. The company will operate under a fee-for-service model that will relieve hospitals of the expense and obsolescence risk of buying capital equipment.

You may also be interested in...



Imaging and the Web

In the ten years or so since picture archiving and communications systems (PACS) were introduced, only 15% of hospitals in the US have implemented them in their radiology departments; the vast majority of hospitals handle most images as they have for years--on film and manually. The reasons are many, but cost is a big factor. Hospitals simply don't have money to pay for expensive PACS. A new business model, the application service provider (ASP) offers a solution. ASPs centralize alot of PACS services, serving multiple clients at once, and archiving digital images off-site at a central location. Hospitals pay on a per transaction basis and avoid the upfront costs of installing capital equipment. The web has made this possible because images can be transmitted over the Internet to off-site storage locations.

Chinese Firms Up Their Game In Novel Flu Antiviral Development

Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.

Quotable: Words Of Wisdom From Our Recent APAC Coverage

Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT037100

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel